Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.
Type:
Grant
Filed:
June 28, 2012
Date of Patent:
June 18, 2013
Assignee:
Biogen Idec MA Inc.
Inventors:
Zoran Sosic, Rulin Qian, James Ahern, Rohin Mhatre
Abstract: A method is provided for early treatment of steatosis, which method is based on early detection of steatosis based on the detection of CD36. CD36 is determined in a body fluid, and CD36 levels above a predetermined value is indicative of steatosis.
Abstract: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed.
Type:
Application
Filed:
February 8, 2013
Publication date:
June 13, 2013
Applicant:
PATHAK HOLDINGS LLC
Inventors:
Chandrashekhar P. Pathak, Sanjay M. Thigle
Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.
Abstract: A method for assessing liver function in an individual, which method comprises determining the level of methylarginine(s) (such as ADMA and/or SDMA) and the ratio of ischemia modified albumin (IMA): albumin ratio (IMAR) in the individual, thereby to assess liver function in the individual.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
June 4, 2013
Assignee:
UCL Business PLC
Inventors:
Rajiv Jalan, Rajeshwar P Mookerjee, Nathan Davies
Abstract: The present invention is a peritoneal function testing method characterized by using a ratio MTACun/MTACc calculated using MTACun and MTACc as an index for a peritoneal function test, where MTACun is an overall mass transfer-area coefficient for urea nitrogen and MTACc is an overall mass transfer-area coefficient for creatinine. The use of MTACun/c of the present invention in this way enables examination of the future peritoneal function of a patient (a mechanism of deterioration in peritoneal function). To be specific, MTACun and MTACc can be obtained by computing Pyle-Popovich model. In addition, the peritoneal function testing method may further calculate a permeability coefficient for cell pores (LPSC) and an overall permeability coefficient (LPS) from Three-Pore Theory model while obtaining a ratio LPSC/LPS calculated using the LPSC and the LPS, and may use the LPSC/LPS ratio and the MTACun/MTACc ratio as indexes for the peritoneal function test.
Abstract: A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating normal mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be administered subcutaneously. The effects of the treatment on the individual can be reflected by clinical tests such as hematological immunological profiles and symptom and signs scores.
Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
Abstract: A peritoneal function testing method uses a ratio of MTACun/MTACc, calculated using MTACun and MTACc, as an index for a peritoneal function test, wherein MTACun is an overall mass transfer-area coefficient for urea nitrogen and MTACun is an overall mass transfer-area coefficient for creatinine. The use of MTACun/MTACc enables examination of the future peritoneal function of a patient (a mechanism of deterioration in peritoneal function). To be specific, MTACun and MTACc can be obtained by computing a Pyle-Popovich model. In addition, the peritoneal function testing method further calculates a permeability coefficient for cell pores (LpSC) and an overall permeability coefficient (LPS) from a Three-Pore Theory model while obtaining a ratio of LPSC/LPS calculated using the LPSC and the LPS. The LPSC/LPS ratio and the MTACun/MTACc ratio can be used as indexes for the peritoneal function test.
Abstract: An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for example as an antioxidant or to decrease or inhibit oxidative stress in a cell, tissue or subject are also described.
Abstract: The invention relates to the determination of the degree of membrane receptor binding by specific monoclonal antibodies. This method is notably beneficial for monoclonal antibodies that are used in targeted therapies in order to define a target effective dose (TED). Especially the invention relates to the determination of the saturation degree of receptor binding effected by an anti-EGFR antibody of interest.
Abstract: Biodegradable detergent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable detergent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.
Type:
Grant
Filed:
September 21, 2011
Date of Patent:
May 7, 2013
Assignee:
DuPont Tate & Lyle Bio Products Company, LLC
Inventors:
Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Raja Hari Poladi, Ann Wehner
Abstract: A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals.
Abstract: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis to occur. The process also includes cooling the mixture of the supernatant and proteinaceous material and optionally acidifying the mixture. This process may also include recovering the solubilized protein from the supernatant for use in various applications. Also provided herein is a composition of solubilized proteins from eggshell membrane obtained using processes of the present invention.
Type:
Grant
Filed:
May 31, 2012
Date of Patent:
April 23, 2013
Assignee:
Biova, L.L.C.
Inventors:
Ronald E. Strohbehn, Lisa R. Etzel, Jesse Figgins
Abstract: System and methods for the detection of biomarkers. In at least one embodiment of a system for the detection of a diagnostic marker in a body fluid of the present disclosure, the system comprises a diagnostic device comprising a plurality of test wells, wherein each test well is capable of containing at least one detection agent, a detection device capable of interacting with the diagnostic device, wherein the detection device is capable of detecting an interaction between the at least one detection agent and a diagnostic marker in at least one of the plurality of test wells, and a stabilization agent contained within at least one of the plurality of test wells, the stabilization agent capable of completely or substantially preventing the degradation or inactivation of the detection agent or the diagnostic marker.
Type:
Grant
Filed:
October 18, 2010
Date of Patent:
April 23, 2013
Assignee:
Companion Diagnostics Inc.
Inventors:
Richard H. Selinfreund, Rakesh Vig, Richard P. Gill
Abstract: The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry.
Type:
Grant
Filed:
March 14, 2007
Date of Patent:
April 16, 2013
Assignee:
Kobenhavns Universitet
Inventors:
Paul Cloos, Karl Agger, Jesper Christensen, Klaus H. Hansen, Kristian Helin
Abstract: Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach.
Type:
Grant
Filed:
November 5, 2011
Date of Patent:
April 16, 2013
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
Type:
Grant
Filed:
April 13, 2012
Date of Patent:
April 16, 2013
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
John O'Connor, Steven Birken, Galina Kovalevskaya
Abstract: The present invention relates to a method for diagnosing chronic obstructive pulmonary disease (COPD) in a human subject or the risk of a human subject to develop COPD comprising the steps of: —providing a sample from a human subject, —determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27), heat shock protein 70 (HSP70) and/or heat shock protein 90 alpha (HSP90 alpha) in said sample, —diagnosing COPD when the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha is increased compared to the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha in healthy human subjects, or—diagnosing the risk to develop COPD when the amount of ccCK-18, histones and/or HSP70 is reduced compared to the amount of ccCK-18, histones and/or HSP70 in healthy human subjects.
Abstract: The dried amniotic membrane is produced by drying a fresh amniotic membrane, which envelopes an embryo of an animal including human, and can be used as a substitute membrane for a membrane tissue in a living body; the dried amniotic membrane is dehydrated and dried so that the dried amniotic membrane can be stored in a dry air in a sterile state; when hydrated again by immersing in water or a buffer solution, the amniotic membrane still has an epithelial cell, a basement membrane and a connective tissue which constitute the fresh amniotic membrane. The dried amniotic membrane is useful as a medical substitute membrane for a membrane tissue in a living body such as a dura mater, a meninx, a pericardium, a pleura and a peritoneum.
Type:
Grant
Filed:
February 21, 2008
Date of Patent:
April 9, 2013
Assignee:
National University Corporation University of Toyama
Abstract: A process for producing a biocompatible material includes the steps of mixing an extract of a fish scale-derived hydroxyapatite (with water content of 70 to 75% by weight) and of a fish scale-derived collagen (with water content of 40 to 60% by weight) in the weight percent ratio of about 8:2, stirring the mixture and drying the mixture by a hot blast in order to obtain a composite.
Abstract: The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
Type:
Grant
Filed:
October 5, 2011
Date of Patent:
April 2, 2013
Assignee:
Tethys Bioscience, Inc.
Inventors:
Michael S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
Abstract: The present invention is about a transdermal method that deliveries nutrients from fresh animal organs to the systemic circulation of the human body by applying the juice or chopped pieces of the fresh animal organs on the skin of the human body and allowing the nutrients to absorb through the layers of the exposed skin. The present invention aims to preserve the Yin and Yang energies naturally present in fresh organs and other foods that are lost in cooking and processing of foods. The present invention uses the full skin area transdermal delivery method by soaking the whole body in the juice of the fresh animal organs as well as the partial skin area transdermal delivery method by exposing certain parts of the human skin area to the fresh juices or chopped fresh animal organs and allowing the nutrients to enter the systemic circulation of the human body.
Abstract: Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.
Abstract: Provided is a simple and easy method of producing an innoxious dry earthworm powder, while suppressing inactivation of the enzymes contained in earthworms. In the method, a homogenate obtained by grinding living earthworms is freeze-dried and the dried product is heat-treated at a temperature of 110° C. or higher but lower than 130° C. Preferably, the method according to the present invention comprises further a process for preparation of the living earthworms, which precedes the grinding step, comprising the steps of: standing the living earthworms under light for 10 to 50 hours; removing the dirt formed on the skin thereof, bringing the earthworms into contact with an organic acid for 30 seconds or less; diluting the acid with addition of water to adjust the pH of the aqueous acidic solution to a pH in the range of 2 to 5; standing the earthworm mixture under the pH condition for 3 to 180 minutes; and then washing the earthworms with water.
Abstract: The present invention relates to a bio-silica chip comprising a silica-binding protein and a fabrication method thereof, and more particularly to a bio-silica chip in which a fusion protein of a silica-binding protein and a probe protein is immobilized on a chip comprising a silica layer, a fabrication method thereof and a method of using the bio-silica chip to detect interactions with biomaterials. The bio-silica chip will be very useful in biosensors, etc., because the bio-silica chip is advantageous in that it does not cause non-specific protein binding in the detection of protein-DNA, protein-ligand, protein-antibody, protein-peptide, protein-carbohydrate, protein-protein and cell-biomaterial interactions. Also, in the method for fabricating the bio-silica chip, a probe chip can be selectively immobilized on a silica device chip, which is widely used in biosensors, without a chemical surface treatment process.
Type:
Grant
Filed:
March 24, 2009
Date of Patent:
March 5, 2013
Assignee:
Korea Advanced Institute of Science and Technology
Inventors:
Sang Yup Lee, Tae Jung Park, Yang Kyu Choi, Bon Sang Gu, Jae Hyuk Ahn
Abstract: Methods to treat skin conditions and diseases by applying Porifera based compositions to the skin are described. Treatable skin conditions and diseases include acne vulgaris, rosacea, seborrheic dermatitis, atopic dermatitis, psoriasis, photo-aging, actinic keratosis and eczema, also known as atopic dermatitis. Therapeutic compositions are obtained from members of Porifera, for example sponges, specifically, fresh water sponges. An example of a fresh water sponge is Spongilla species. One specific therapeutic composition is obtained from Spongilla species and formulated with pharmaceutical excipients.
Abstract: The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
February 12, 2013
Assignees:
Case Western Reserve University, Brigham and Womens Hospital, The University of Washington
Inventors:
David M. Lee, Eric Boilard, Michael H. Gelb, Reuben Gobezie
Abstract: The invention provides methods and kits for detecting conformationally altered proteins, such as prions or other proteins associated with disease states, in a sample. The methods comprise selectively capturing and separating complexes of peptide and conformationally altered protein from substances that interfere with detection of such complexes, and preferably amplification of the detection signal b addition of a second double-labeled peptide.
Abstract: A biological nerve guide for implantation into a human body is made by providing a natural animal tissue membrane, crosslinking and fixing the membrane, minimizing the antigens from the membrane, tanning the membrane, coupling an active layer to an inner surface of the membrane, cutting the membrane into a desired shape and size, positioning the cut membrane onto a rod-shaped mold so that the cut membrane assumes a cylindrical configuration, and attaching a spiral support to the outer surface of the cut membrane.
Abstract: The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.
Type:
Grant
Filed:
May 7, 2007
Date of Patent:
February 5, 2013
Assignees:
Historx, Inc., Yale University
Inventors:
Mark Gustavson, Jennifer Giltnane, Marisa P. Dolled-Filhart, Robert L. Camp, David L. Rimm
Abstract: The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.
Abstract: This invention concerns a composition for regulating lipid metabolism and methods that may be used in the food industry as well as in the nutraceutical and therapeutic fields. In particular, the invention involves food additives or supplements, a composition containing these and the use thereof, in particular for revitalizing a subject's metabolism, in particular, that of human beings.
Type:
Grant
Filed:
October 16, 2008
Date of Patent:
January 29, 2013
Assignee:
Actigenomics S.A.
Inventors:
Marie Francoise Yvonne Bourgeois-Lugand, Walter Wahli, Ilhem El Kochairi, Sylvain Pradervand, Giles Didier Parisot
Abstract: The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.
Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
January 29, 2013
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.
Abstract: Methods of promoting reproductive health in an animal by administering an effective amount of a composition containing at least one transfer factor are provided.
Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.
Abstract: This is a potent drug with narcotic benefits made from distinctly and uniquely combined and processed interchangeable seed and seed derivatives that are so potent that it removes or alleviates depression, mood disorders, Attention Disorder symptoms, thought disorder, mental illness, pain, right lip retardation symptoms, physical problems, Lymph Node cancer and many other illness symptoms. It removes bumps in the neck within a week or two. It is interchangeable in most aspects. It can be combined and processed with Pharmaceuticals and medicines to create new drugs. These Pharmaceuticals are now long lasting. I prefer the daily dose, but this drug can last months. It is extremely strong or potent and can be made weak to make your little Attention deficit child normal. It is an incredible mood stabilizer and reduces psychosis. Use it for cancer patient and for people with pain issues. It works.
Abstract: Methods and kits for the quantitation of cellular DNA and cell numbers are provided. Passive element uptake, element-labeled DNA intercalators, and element labeled affinity reagents are used to quantify DNA and cells. The DNA and the cells are analyzed by elemental analysis, including ICP-MS. The methods and kits provide a fast and accurate analysis of cellular DNA and cell numbers.
Abstract: The present invention relates generally to detection of occult blood. In particular, the present invention provides a device and methods for the simultaneous detection of hemoglobin and transferrin in fecal samples, which permit a more sensitive diagnosis of occult blood in fecal sample and a differential diagnosis of bleeding of the upper GI tract versus the lower GI tract.
Abstract: A biofilm-inhibiting medical product includes a carrier formed from a natural, bioremodelable material, whereby the carrier includes a biocidal bismuth thiol agent and/or one or more other biofilm-inhibiting or wound healing agents. A method for using the biofilm-inhibiting medical product to treat a wound or tissue defect in a patient's body is described.
Type:
Grant
Filed:
January 24, 2008
Date of Patent:
January 1, 2013
Assignees:
Cook Biotech Incorporated, Cook Medical Technologies LLC
Inventors:
Brian L. Bates, Michael C. Hiles, Chad E. Johnson
Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.
Type:
Grant
Filed:
May 11, 2010
Date of Patent:
December 25, 2012
Assignees:
The General Hospital Corp., ViaCord, LLC
Inventors:
Morey Kraus, Seth Finklestein, Paul Clark
Abstract: Methods for the degradation of prion proteins are described. Items that may be contaminated with prions are treated with earthworm-derived extracts to degrade prion proteins and reduce their infectivity in animals. Methods of using an earthworm-derived protein extract for treating foodstuffs and surfaces to inhibit or disable prion infectivity are disclosed. Also disclosed are methods for treating medical instruments, tools used to butcher animals, and laboratory equipment.
Abstract: Method of using saponins from at least one plant of the Gleditsia genus, or an extract of at least one plant of the Gleditsia genus including saponins, for controlling, by ingestion, land or aquatic mollusc pests. The molluscicidal active principle, compositions containing the same, and methods for controlling mollusc pests are also described.
Type:
Application
Filed:
February 9, 2011
Publication date:
December 20, 2012
Applicant:
DE SANGOSSE
Inventors:
Xavier Crebassa, Herve Caruel, Frederic Mercier, Ricardo Manuel Guillermo San Martin Gamboa
Abstract: The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.
Type:
Application
Filed:
February 28, 2011
Publication date:
December 20, 2012
Applicant:
FRESENIUS MEDICAL CARE DEUTSCHLAND G.M.B.H.
Inventors:
Stefania Bruno, Maria Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.